BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
May 17, 2010
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Synta preclinical data

In a mouse xenograft model of Tarceva erlotinib-resistant NSCLC, STA-9090 plus paclitaxel or Avastin bevacizumab led to greater reductions in average tumor volume compared to any of the agents alone. In a mouse xenograft model...

Read the full 164 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >